Senicapoc

DB06280InvestigationalSmall molecule

Senicapoc (ICA-17043) is a novel Gardos channel blocker. It is being investigated for the treatment of sickle cell disease.

Mechanism: Pharmacologically active on Intermediate conductance calcium-activated potassium channel protein 4
Curator reviewed
Primary indication: Investigated for use/treatment in anemia (sickle cell) and asthma.Curator reviewed
Formula / weight: C₂₀H₁₅F₂NO · 323.343 g/mol (avg)
Also known as: 2,2-Bis(4-fluorophenyl)-2-phenylacetamide · Bis(4-fluorophenyl)phenylacetamide
Code names: ICA-17043 · PF-05416266

Resolves to

Compound

Structure

InChIKeySCTZUZTYRMOMKT-UHFFFAOYSA-NSMILESNC(=O)C(C1=CC=CC=C1)(C1=CC=C(F)C=C1)C1=CC=C(F)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Senicapoc, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.